Psychedelics Psyence BioMed invests half a million into natural psychedelics operator PsyLabs In conjunction with the financing, Psyence has secured the option to receive a steady supply of ibogaine from PsyLabs Rowan Dunne2 days ago
Medical and Pharmaceutical 60 Degrees Pharma signs patent agreement with Yale for tick disease medicine development The newly announced partnership sent shares up by 137% at the intraday peak on the Nasdaq Tuesday Rowan DunneApril 8, 2025
Psychedelics Intranasal delivery tech developer ‘Polyrizon’ plans to administer psychedelics The Israeli company has an unnamed new partner involved with unspecified psychedelic drugs Rowan DunneMarch 18, 2025
Beverages Quantum BioPharma soars on clinical trial success with ‘unbuzzd’ hangover cure supplement Shares are currently up by over 110% on the Nasdaq Rowan DunneFebruary 4, 2025
Medical and Pharmaceutical bioAffinity Technologies secures Australian patent for ‘CyPath Lung’ spit test It will be issued within 3 months provided that there are no opposition filings made by third parties Rowan DunneJanuary 22, 2025
Gold ‘It wasn’t our fault’: SSR Mining links Çöpler landslide to 3rd party engineering mistake A heap leach pad failure last February caused a catastrophic incident that killed 9 people Rowan DunneJanuary 16, 2025
Medical and Pharmaceutical SILO Pharma flies high on impending patent for intranasal PTSD drug The stock rose by 146% in early morning trading on the Nasdaq Rowan DunneJanuary 8, 2025
Medical and Pharmaceutical RAPT Therapeutics sees 113% spike on allergy med licensing deal & private placement The biotech operator can develop and commercialize Jemincare's food allergy medication throughout most of the world Rowan DunneDecember 23, 2024
Psychedelics Psychedelic drug developer MindMed set for listing on Nasdaq Biotechnology Index MindMed's lead drug candidate is an LSD-like therapeutic used to treat anxiety Rowan DunneDecember 20, 2024
Cannabis Weedmaps parent company stock spikes after proposition to go private The multi-purpose cannabis platform operator has been on a steady decline since it went public in 2021 Rowan DunneDecember 18, 2024